Background: The Dyspnoea-12 (D-12) is a well validated instrument in respiratory illnesses for breathlessness assessment, but its psychometric properties have not been tested in lung cancer.
Introduction
Breathlessness is defined as "a subjective experience of breathing discomfort that consists of qualitatively distinct sensations that vary in intensity" [1] . It is one of the most distressing symptoms frequently identified in lung cancer, which occurs in over 80% of lung cancer patients [2] [3] [4] [5] . Evidence supports breathlessness as a multidimensional experience, as the presence of breathlessness is associated with physical and emotional distress such as fatigue, anxiety, depression, and deterioration of quality of life (QoL) [2, 5, 6] . As breathlessness is a subjective symptom involving both physical and psychological factors, its measurement should be multidimensional using patient-reported approaches that encompass its different dimensions [1, 7] .
There is a plethora of instruments for assessing breathlessness, although most of them have been validated for chronic obstructive pulmonary disease (COPD) [8] . Commonest used unidimensional tools for breathlessness assessment include the modified Borg scale, visual analogue scale (VAS) and numerical rating scale (NRS) [8, 9] . Although these tools are easy to complete, the use of different endpoints makes it difficult to do comparisons between studies [8] , and their unidimensional nature requires the use of multiple instruments to obtain a full understanding of breathlessness. The Medical Research Council (MRC) dyspnoea scale is also a popular tool for grading breathlessness [8] . However, it is only activity-specific and it is weak in its association with patients' physical and functional distress, which make it impossible to use for the multidimensional assessment of breathlessness [8, 10] .
Multidimensional instruments for breathlessness assessment have also been introduced, such as the Cancer Dyspnoea Scale (CDS) [11] [12] [13] . But the CDS only includes the anxiety as patients' psychological distress and the evidence in terms of its responsiveness and minimal clinically important difference (MCID) is lacking [11] [12] [13] [14] . The Chronic Respiratory Questionnaire (CRQ) is a good candidate for breathlessness assessment [14] . It has been well validated in chronic respiratory diseases [14] , and the psychometric properties of its short form have also been preliminarily identified in lung cancer [15] . However, the patient may take a relatively long time to complete the entire questionnaire [16] , and it seems to be most appropriate for use in patients without any acute breathlessness [14] . Small changes in breathlessness may also not be captured by repeated administration of the CRQ [17] . Another tool named Breathlessness Assessment Guide has also been developed for lung cancer without any psychometric testing [18, 19] .
The Dyspnoea-12 (D-12) is a convenient patient-reported scale for measuring the severity of breathlessness [20] . Breathlessness is quantified by using 12 descriptors to cover both its physical and psychological dimensions [20] . The D-12 has established its validity and reliability in COPD [20] , asthma [21] , interstitial lung disease [22] and pulmonary hypertension [23] , which indicates its promising role for measuring breathlessness in a wide range of conditions. Psychometric properties of the D- 12 have not yet been assessed in lung cancer. Therefore, the aim of this study was to determine the validity and reliability of the D-12 in lung cancer, by using data from a recent feasibility randomised controlled trial (RCT) [24] .
Materials and Methods
Research ethical approval was granted to this study, and research governance approval was also received from the study hospitals. All participants provided written informed consent.
Overview of the Feasibility Trial
This was a multi-centre, non-blinded feasibility RCT conducted in the UK [24] . It aimed to feasibility test a non-pharmacological intervention for managing the lung cancer respiratory distress symptom cluster (breathlessness-cough-fatigue). A total of 107 lung cancer patients joined the study and 101 were included in the analysis. Participants completed self-reported outcome measures including a range of scales to assess symptoms, psychological distress and QoL [24] . In the current study, only baseline data were used for the analysis.
Study Instruments
The most pertinent outcome measures for examining the D-12 psychometric properties were included in this analysis.
Dyspnoea-12 Questionnaire (D-12)
The D-12 uses 12 items to generate a global assessment of the severity of breathlessness [20] .
Each item is rated on a 4-point Likert scale from 0 (none) to 3 (severe), and the total scores range from 0 to 36 with a higher score indicating more severe dyspnoea [21] [22] [23] . Items 1 to 7 are summed up to create the physical component score, and items 8 to 12 are used for calculating the emotional component score [21, 23] . MCID of the D-12 has been determined in the lung cancer feasibility RCT with a value of three units [24] .
NRS Breathlessness Scales
Five 0-10-point NRS scales were adopted to measure the average and worst breathlessness experienced during the past 24 hours (higher scores=worse conditions), breathlessness-related unpleasantness and distress (higher scores=worse conditions), and patients' ability to cope with breathlessness (higher scores=better conditions) [24] [25] [26] . The NRS were used to explore the associations with the D-12 total and component scores.
Hospital Anxiety and Depression Scale (HADS)
HADS is a well validated self-reported instrument for determining the general state of psychological distress [27, 28] . It has 14 items with 7 each measuring anxiety and depression respectively [27, 28] .
Each item is rated from 0 to 3, thus the scores for either anxiety or depression scale range from 0 to 21 (higher scores=more severe outcomes) [27, 28] . For a particular statistical purpose, a HADS anxiety score HADS anxiety score of 8 or above was suggested as the presence of anxiety and a HADS depression score of 8 or above was indicated as the presence of depression [28, 29] .
Lung Cancer Symptom Scale (LCSS)
The LCSS is a QoL assessment tool with well documented psychometric properties [30, 31] . The LCSS patient-reported scale consists of nine items with six assessing prominent symptoms related to lung cancer and another three evaluating patients' "symptomatic distress", "activity status" and "overall QoL" [30] . All items use the 0-100 VAS scale (higher scores=worse outcomes) and the total score is computed as the mean of all the nine items [32] . The LCSS was used to explore its correlations with the D-12 as QoL in lung cancer has been proved to be negatively associated with dyspnoea [5] .
Psychometric Assessment

Reliability and Validity
Internal consistency reliability for the D-12 was examined and the item-to-total correlations were adopted to explore the relationships between one single D-12 item score and the total D-12 score without that item [33] . Validity was examined by convergent validity and construct validity. Convergent validity is estimated by examining "whether the measured variables correlate with other measures of the same concept" [34] . Associations between the D-12 and the NRS, HADS and LCSS were explored to identify the D-12 convergent validity. Exploratory factor analysis (EFA) was applied to estimate the D-12 construct validity.
Acceptability, Floor and Ceiling Effects, Invariance and Discriminate Performance
Acceptability of the D-12 was estimated by calculating the percentage of missing value across all the D-12 items. Percentages of the subjects who had the lowest and highest possible D-12 total score were computed respectively to estimate the floor and ceiling effects of the D-12. Invariance of the D-12 was tested for age and gender factors. Discriminate performance analyses were considered for subjects with or without anxiety, depression and COPD.
Statistical Analysis
The IBM SPSS Statistics for Windows version 22.0 (IBM Corp, Armonk, NY, USA) was adopted for data analysis with the statistical significance setting as P ˂0.05. Descriptive statistics were presented to summarise patients' demographic data, acceptability, and the floor and ceiling effects of the D-12.
Spearman's correlation coefficients (rs) were adopted for exploring the associations between the D-12 and the NRS, HADS and LCSS, as most of the instrument scores in our sample violated the assumption of normal distribution. Principal component analysis (PCA) with a varimax rotation (eigenvalues ˃1) was used for the EFA. Items that loaded ˃0.6 were retrieved for a potential factor. Independent-samples t-test or Mann-Whitney U test (as determined by the normality test) was adopted to estimate the D-12 score difference in different subgroups (e.g. male vs. female, anxious vs. not anxious, depressed vs. not depressed, and COPD vs. non-COPD). Age difference was analysed by exploring the association (rs) between the D-12 and patients' age. Internal consistency was estimated by Cronbach's alpha, and an alpha score of 0.8 or above is determined as very good for an instrument [35] . An item-to-total correlation is viewed as adequate once the value reaches 0.4 [36] .
Results
Patients' Demographic and Clinical Data
One hundred and one participants were included for analysis. The majority of the patients were aged over 60 years old and around one third of them presented anxiety or depression ( Table 1) .
D-12 Descriptive Analysis
The mean score for D-12 total was 17.8 (SD=9.4), and it was 11.0 (SD=5.3) and 6.6 (SD=4.8) for D-12 physical and D-12 emotional subscale, respectively. Missing values within the D-12 were identified in no more than four subjects for each item across items 1 to 8, with the percentage of missing data per item ranging from 1.0% to 4.0%. No missing data were detected for items 9 to 12. Proportions of the patients with the lowest (0) and possibly highest score (as of 35 in this sample) of the D-12 total were 4.0% (4/101) and 1.0% (1/101) respectively.
D-12 Convergent Validity
D-12 scores were strongly and positively correlated with HADS and LCSS score (all at P˂0.001). The highest rs was identified between D-12 emotional subscale and HADS anxiety subscale (rs=0.71, P˂0.001). For the associations between the D-12 and NRS, significantly positive correlations can be found between D-12 and NRS "average" and "worst" breathlessness, and "distress" and "unpleasantness" associated with breathlessness (rs ranged from 0.48 to 0.64, all at P˂0.001).
Slightly negative (but insignificant) correlations were shown between D-12 and NRS "ability to cope with breathlessness" (P˃0.05) ( Table 2) .
D-12 Construct Validity
There were two well-defined factors with items 1 to 7 clustering around the first factor (coefficients ranged from 0.68 to 0.81, representing the physical dimension of breathlessness) and items 8 to 12 gathering around the second factor (coefficients ranged from 0.78 to 0.87, indicating the emotional dimension of breathlessness) ( Table 3 ).
D-12 Reliability
Internal consistency of the entire D-12 questionnaire was identified as excellent, as already reported in the feasibility study paper, with the Cronbach's alpha of 0.95 [24] . Internal consistency for the D-12 physical and emotional subscales was also excellent, with Cronbach's alpha being 0.92 and 0.94, respectively. Adequate item-to-total correlations of the D-12 were identified, with the coefficients ranging from 0.59 to 0.84 (mean 0.8).
D-12 Invariance and Discriminate Performance
There was no difference in D-12 scores between male and female patients (all at P ˃0.05), and Spearman's correlation also showed no association between D-12 and age (rs ranged from -0.15 to -0.12, all at P ˃0.05). Patients with anxiety or depression presented significantly higher D-12 scores than those without anxiety or depression (all at P˂0.001) ( Table 4) . Similarly, patients with COPD also had significantly higher D-12 scores than non-COPD patients (all at P˂0.05, Table 5 ).
Discussion
The D-12 is a short scale confirming earlier reports in non-cancer populations that has minimal missing data [23] . Acceptability of the D-12 was documented, as missing values across items and the floor and ceiling effects were minimal in the lung cancer sample. Given the good completion rate of the D-12 and its ability to gain an overall score that incorporates multidimensional aspects of dyspnoea severity, the clinical utility of the D-12 seems promising.
Convergent validity of the D-12 was adequate. The significantly positive associations between the D-12 and the NRS scales indicated the possibility of using one single instrument instead of multiple tools to measure the overall severity of breathlessness. There was a negative (but insignificant) correlation between the D-12 and patients' coping ability, which indicted that severe dyspnoea might impair the patients' ability to cope with the symptom. However, it is also suggested that the distress induced by the symptoms emotional component might, in turn, motivate patients' behaviour [21] . The potentially bidirectional function of psychological distress might partially contribute to the above insignificant correlation. As coping ability is a complex construct which is almost impossible to capture in a single item scale, its relationship with dyspnoea is worthy of further exploration.
The D-12 was strongly correlated with anxiety and depression, as both the HADS and the D-12 possess the psychological construct that measures patients' emotional status. Theoretically, D-12 emotional subscale would be expected to correlate more strongly with the HADS than the D-12 physical subscale, and this assumption was also precisely captured in our findings. Similar to our previous findings [21] [22] [23] , correlations between D-12 and HADS were only moderate. This suggested the difference of the focus of emotional distress between D-12 and HADS, with the former capturing the emotional status related to dyspnoea and the latter focusing more on the general status of emotional problems [23] .
Breathlessness is a negative predictor of QoL in lung cancer, as severe shortness of breath impacts upon the patients' ability to maintain daily physical and functional well-being [2, 5, 37] . Our findings support this statement as significant correlations were shown between D-12 and LCSS. Factor analysis supported very good construct validity of the D-12, which was highly consistent with the factor analysis result during the development stage of the D-12 [20] .
It is not surprising that no gender and age difference was detected across D-12 scores, as age and gender have been reported not to be related to dyspnoea in lung cancer [6] . Also, during the D-12 development stage, items with gender or age bias had already been abandoned [20, 22] . Patients with anxiety or depression experienced more severe dyspnoea than those without such affective distress, as expected, because emotional problems such as anxiety and depression have been noted to be closely associated with breathlessness distress in lung cancer [6, 38, 39] .
Breathlessness is one of the leading symptoms in COPD [40, 41] COPD patients tend to experience similar or more severe dyspnea and impaired QoL than that in lung cancer patients at a comparable advanced disease stage [42] [43] [44] . Lung cancer patients with COPD are expected to experience more severe dyspnea than those without COPD, and this was accurately captured by the D-12 as patients with COPD had significantly higher D-12 scores than non-COPD patients.
The study has some limitations. Sample size estimation in the feasibility trial was not powered for the purpose of estimating psychometric properties. Stability of the D-12 has been documented in previous studies [20] [21] [22] [23] , but the cross-sectional nature of the current study made it impossible to examine the D-12 test-retest reliability in lung cancer. Despite these limitations, our study demonstrated that the D-12 is a valid and reliable assessment for breathlessness in lung cancer. use in future lung cancer trials to measure patients' breathlessness severity.
Conclusion
D-12 is a valid and reliable patient-reported instrument for measuring breathlessness, including both its physical and emotional aspects, in patients with lung cancer. Future lung cancer studies are encouraged to adopt the D-12 as one of the outcome measures for breathlessness assessment. 
